Candriam S.C.A. Has $15.78 Million Position in TransMedics Group, Inc. $TMDX

Candriam S.C.A. increased its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 45.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 158,766 shares of the company’s stock after acquiring an additional 49,580 shares during the period. Candriam S.C.A.’s holdings in TransMedics Group were worth $15,783,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the company. Royal Bank of Canada boosted its holdings in shares of TransMedics Group by 47.9% in the 1st quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock valued at $1,788,000 after purchasing an additional 8,604 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of TransMedics Group by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock valued at $1,314,000 after purchasing an additional 868 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of TransMedics Group by 20.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after buying an additional 86,721 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of TransMedics Group by 13.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock worth $1,059,000 after buying an additional 938 shares in the last quarter. Finally, M&T Bank Corp bought a new stake in shares of TransMedics Group during the 2nd quarter worth $209,000. 99.67% of the stock is owned by institutional investors.

TransMedics Group Trading Down 1.3%

TransMedics Group stock traded down $0.96 during trading hours on Friday, hitting $71.23. The stock had a trading volume of 455,584 shares, compared to its average volume of 996,398. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. The stock has a market cap of $2.46 billion, a price-to-earnings ratio of 16.19 and a beta of 1.89. TransMedics Group, Inc. has a one year low of $60.10 and a one year high of $156.00. The business’s 50 day simple moving average is $71.52 and its 200-day simple moving average is $106.40.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The firm had revenue of $173.93 million for the quarter, compared to the consensus estimate of $174.44 million. During the same quarter last year, the firm posted $0.70 earnings per share. The business’s revenue for the quarter was up 21.2% on a year-over-year basis. On average, equities analysts predict that TransMedics Group, Inc. will post 1.92 EPS for the current fiscal year.

Insiders Place Their Bets

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the sale, the director directly owned 16,642 shares of the company’s stock, valued at $1,249,148.52. The trade was a 36.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

TMDX has been the topic of a number of recent analyst reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $124.00 target price on shares of TransMedics Group in a research report on Tuesday, June 30th. UBS Group restated a “hold” rating on shares of TransMedics Group in a research note on Tuesday, May 26th. Wall Street Zen lowered shares of TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Zacks Research cut shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a research report on Monday, July 6th. Finally, Oppenheimer downgraded shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 6th. Six analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, TransMedics Group currently has a consensus rating of “Hold” and a consensus target price of $134.50.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.